Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

The Times of India has launched the #AdsWeLove platform, allowing users to explore a range of creative print advertising campaigns. This platform showcases campaigns from publications like The ...

BUFFALO, N.Y. — In January, Nicole Albanese, PharmD, clinical associate professor of pharmacy practice in the University at ...

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...

This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in quarterly sales, although it was approved only in late 2023. Zepbound's prospects still ...

Last weekend, the company expanded the campaign to add full-page print ads in The New York Times, The Wall Street Journal, The Washington Post, The Detroit News, The Detroit Free Press and other ...

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its diabetes treatment Mounjaro, the company's latest attempt ...

Lilly sells tirzepatide as Mounjaro for type 2 diabetes and Zepbound for obesity. In the complaints, Lilly alleges that the telemedicine companies are marketing tirzepatide mixed with substances ...